• Explore /
  • Poster
  • / Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.

Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.

Abstract Poster

Authors

null

Josep M. Piulats

Catalan Institute of Oncology, Barcelona, Spain

Josep M. Piulats , Luis De La Cruz-Merino , Maria Teresa Curiel Garcia , Alfonso Berrocal , Lorenzo Alonso-Carrión , Enrique Espinosa , Rafael López Castro , Delvys Rodriguez-Abreu , Pablo Luna Fra , Salvador Martin-Algarra

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

2015-004429-15

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9533)

DOI

10.1200/JCO.2017.35.15_suppl.9533

Abstract #

9533

Poster Bd #

141

Abstract Disclosures

Similar Posters

First Author: Jose Maria Piulats Rodriguez

First Author: Sophie Piperno-Neumann

First Author: Dirk Schadendorf

First Author: Joseph J. Sacco